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Abstract
The Adult Changes in Thought (ACT) study is a long-running prospective study
of incident all-cause dementia and Alzheimer’s disease (AD). As the cohort ages, death
(a terminal event) is a prominent competing risk for AD (a non-terminal event), al-
though the reverse is not the case. As such, analyses of data from ACT can be
placed within the semi-competing risks framework. Central to semi-competing risks,
and in contrast to standard competing risks, is that one can learn about the de-
pendence structure between the two events. To-date, however, most methods for
semi-competing risks treat dependence as a nuisance and not a potential source of
new clinical knowledge. We propose a novel regression-based framework that views
the two time-to-event outcomes through the lens of a longitudinal bivariate process on
a partition of the time scale. A key innovation of the framework is that dependence
is represented in two distinct forms, local and global dependence, both of which have
intuitive clinical interpretations. Estimation and inference are performed via penal-
ized maximum likelihood, and can accommodate right censoring, left truncation and
time-varying covariates. The framework is used to investigate the role of gender and
having ≥1 APOE-4 allele on the joint risk of AD and death.
Keywords: Alzheimer’s disease; B-splines; discrete-time survival; longitudinal modeling;
penalized maximum likelihood; semi-competing risks
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1 Introduction
Alzheimer’s disease (AD) is a brain disorder characterized by progressive dementia that
slowly destroys memory and cognitive function. In 2018, an estimated 5.7 Americans were
living with AD [1]. First described in 1906, research over the last 40 years has identified
numerous risk factors for AD, including: age, family history, the apolipoprotein E (APOE)-
4 allele, midlife obesity, midlife hypertension, and diabetes [2]. Factors that exhibit a
protective effect include education and physical activity [2].
Many of these factors are also strongly associated with mortality. This suggests that
the outcomes of AD and mortality may be dependent within individuals and, furthermore,
that this dependence may be influenced by a range of factors. One way of framing such
dependence is through consideration of whether and how AD influences the risk of death.
This could be achieved by, say, fitting a Cox model with death as the endpoint and AD as
a time-varying covariate. While informative, this approach shifts attention away from AD
as an outcome. Moreover, it precludes viewing AD and death as a multivariate outcome
for which the components may exhibit covariation. This latter framing, we believe, may
be of substantial interest to individuals who are alive and cognitively intact.
Practically, studies of risk factors for AD often focus on the timing of a diagnosis and
thus use survival analysis methods. Typically, such analyses often treat death as a censoring
mechanism in the observed data. An alternative is the semi-competing risks paradigm
which would consider AD and mortality simultaneously. In general terms, semi-competing
risks refers to the setting where interest lies in some non-terminal time-to-event outcome,
the occurrence of which is subject to a terminal event [9, 37, 12]. Let T1 and T2 denote
the time to the non-terminal and terminal events, respectively. Key to semi-competing
risks is that one can potentially observe both T1 and T2 on individual study units. As
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such, in contrast to the standard competing risks setting, there is partial information on
the joint distribution of the non-terminal and terminal events in the semi-competing risks
setting [35, 15]. This, in turn, provides an opportunity to learn about the dependence
structure between T1 and T2.
Beyond the usual challenges of time-to-event analyses (i.e. structuring covariate effects,
handling functions of time, and accommodating various forms of censoring and truncation),
key challenges that arise in the analysis of semi-competing risks data are: (i) respecting
the terminal event as a competing risk; and, (ii) structuring dependence between T1 and
T2. In the statistical literature, numerous frameworks for the analysis of semi-competing
risks data have been proposed, including: methods grounded in causal inference [42, 6, 33];
methods based on structuring dependence via a copula [9, 29, 14, 24]; the use of illness-death
models [39, 22, 21]; and, the recently-proposed cross-quantile residual ratio [40]. While
additional review details are provided in Section A.1 of the Supplementary Materials, we
note that these methods either: (i) view dependence as a statistical nuisance, and not a
potential source of new clinical knowledge; or, (ii) focus on the role of the non-terminal
event as a risk factor for the terminal event, thereby reframing the non-terminal event
away from being an outcome of interest. As such, collectively, these methods fail to take
advantage of the opportunity to learn about dependence between the two outcomes that
semi-competing risks data provide.
In this paper we propose a novel regression-based framework for semi-competing risks
data that simultaneously structures covariate effects on T1 and on T2, as well as on the
dependence between the two events. A key innovation of the proposed framework is that
dependence is represented in two distinct forms, termed the local and global dependence,
both of which have intuitive clinical interpretations. Practically, smoothness in model
components that are functions of time is facilitated through the use of B-splines, with
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estimation and inference via maximum penalized likelihood. Since the modeling framework
is based upon probabilities conditional on survival, left truncation, right censoring and
time-varying covariates may be accommodated in a straightforward manner.
2 The Adult Changes in Thought study
The Adult Changes in Thought (ACT) study is an on-going community-based prospective
study of incident all-cause dementia and AD among the elderly in western Washington
state [19]. Initiated in 1994, the goals of the study are to learn about how the brain
ages and to identify risk factors for AD. In this paper, we consider data on N=4,367 ACT
participants, who were enrolled between 1994-2015, and who were aged 65 years or older and
cognitively intact at the time of enrollment. Table A.1 of Section A.2 in the Supplementary
Materials provides a summary of key participant characteristics measured at study entry,
including: age, gender, race, marital status, education, co-morbid depression, and APOE
4 carrier status.
Follow-up in ACT consists of biennial visits during which co-morbidities and clinical
histories are updated, and during which participants undergo a comprehensive evaluation
the result of which may be a diagnosis of AD. For the purposes of this paper, follow-up
time was administratively censored at the first of December, 2016 or age 99 years. Based on
these criteria 205 (5%) were diagnosed with AD during follow-up but were censored prior
to death, 818 (19%) were diagnosed with AD and died during follow-up, 1,613 (37%) died
during follow-up without a diagnosis of AD; and, 1,731 (39%) were censored prior to either
a diagnosis of AD or experiencing death. Figure 1 provides a summary of the observed
person-time for the patients. Within each panel, the patients have been ordered by: (i)
their age at entry and (ii) the age at which their eventual outcome status is observed.
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Figure 1: Summary of person-time while on-study among N=4,367 participants in the
ACT study, stratified by whether they had a diagnosis of AD and/or died during follow-
up. Within each sub-figure, participants are ordered first by their age of enrollment and
second by their observed event/censoring time.
3 A longitudinal bivariate modeling framework
As indicated in the Introduction, a common theme across existing approaches to the anal-
ysis of semi-competing risks data is that they generally view dependence between the
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non-terminal and terminal events as a (statistical) nuisance and not a potential source of
new clinical knowledge. In this Section we propose a novel longitudinal bivariate mod-
eling framework for semi-competing risks within which dependence between T1 and T2 is
characterized in a meaningful and interpretable way, and is permitted to be a function of
covariates.
3.1 A novel representation of semi-competing risks data
The proposed framework builds on a novel representation of observed semi-competing risks
outcome data. Prior to describing this, it is useful to consider how such data are typi-
cally represented. Towards this, let L and C denote the study entry and right censoring
times, respectively. The observed outcome data for the ith study participant is Di =
(Li, T˜1i, δ1i, T˜2i, δ2i), where T˜1i = min(T1i, T2i, Ci), T˜2i = min(T2i, Ci), δ1i = I{T˜1i = T1i},
and δ2i = I{T˜2i = T2i}. Note, δ1i and δ2i indicate whether the study unit is observed to
experience the non-terminal event and terminal event, respectively.
Let τ = {τ0, . . . , τK} be a set of user-specified points, with τk−1 < τk for k = 1, . . . , K,
that define a partition of the analysis time scale. Towards the study of AD using data from
the ACT study, for example, one could choose age beyond 65 years as the time scale and
τ = {65, 70, 75, ..., 100}. Let Y1i,k = I{T1i ≤ τk} and Y2i,k = I{T2i ≤ τk} be indicators
of whether participant i experienced the non-terminal and terminal events by time τk,
respectively. Furthermore, let kli ∈ {1, . . . , K} be the index of the first time point in τ
after Li and k
r
i ∈ {1, . . . , K} the index of the first time point in τ after T˜2i. The observed
outcome data on the partition τ can then be represented as a longitudinal bivariate process,
specifically Y i = {(Y1i,k, Y2i,k); k = kli, . . . , kri }. Figure A.1 in the Supplementary Materials
provides a graphical representation of the observed outcome data for four hypothetical
study participants.
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Finally, let X i(τk) denote a vector of possibly time-dependent covariates measured at
time τk−1. Given this, let X i,k = (X i(τ1), . . . ,X i(τk)) denote the history of all covariate
information (i.e. both time-invariant and time-varying) up to time point τk−1.
3.2 The joint distribution of the observed data
Let X i ≡X i,kri is the totality of all covariate data observed for the ith participant. At the
outset we assume that the joint distribution of the observed outcome data for the ith study
participant, P(Y i = yi| X i), can be decomposed as the product:
kri∏
k=kli
P(Y1i,k = y1i,k, Y2i,k = y2i,k| Y1i,k−1 = y1i,k−1, Y2i,k−1 = y2i,k−1,X i,k), (1)
where we define Y1i,0 = Y2i,0 = 0. Underpinning this decomposition is a Markov-type
assumption that the joint probability of the two events in a given interval depends on
the history of the two events solely through what is known at the start of the interval,
conditional on the totality of the covariate information to that point.
As shown in Section A.4 of the Supplementary Materials, the components of expression
(1) can be written in terms of:
pi1i,k = P(Y1i,k = 1| Y1i,k−1 = 0, Y2i,k−1 = 0,X i,k) (2)
pi2i,k(y1) = P(Y2i,k = 1| Y1i,k−1 = y1, Y2i,k−1 = 0,X i,k) (3)
θi,k = OR(Y1i,k, Y2i,k| Y1i,k−1 = 0, Y2i,k−1 = 0,X i,k) (4)
for y1 = 0, 1 and where
OR(Y1i,k, Y2i,k| . . .) = P(Y1i,k = 1, Y2i,k = 1| . . .)× P(Y1i,k = 0, Y2i,k = 0| . . .)
P(Y1i,k = 0, Y2i,k = 1| . . .)× P(Y1i,k = 1, Y2i,k = 0| . . .) .
We emphasize that the interpretations of these three quantities are specific to the partition
τ . Specifically, pi1i,k is the cumulative probability of experiencing the non-terminal event
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by time τk, given that neither event had occurred by time τk−1. Similarly, pi2i,k(·) is the
cumulative probability of experiencing the terminal event by time τk, given that the indi-
vidual is alive at time τk−1. Note, both of these correspond to quantities that are modeled
in discrete time survival analyses [23, 30]. Finally, θi,k is the cross-sectional odds ratio for
the 2×2 table corresponding to the four possible observed (Y1i,k, Y2i,k) outcome vectors at
time τk, given that neither the non-terminal nor the terminal event had occurred by time
τk−1. Given its clear importance, we return to the choice of τ in Section 3.5.
3.3 Regression structure
We proceed with modeling by placing structure on the components given by expressions
(2)-(4) as a function of covariates. Specifically, we propose that pi1i,k, pi2i,k(·), and θi,k be
modeled via the following regressions:
pi1i,k = g
−1
1 {α1,k + f1(X i1,k;β1)} (5)
pi2i,k(y1) = g
−1
2 {α2,k + f2(X i2,k, Y1i,k−1;β2)} (6)
θi,k = g
−1
θ {αθ,k + fθ(X iθ,k;βθ)}, (7)
where g1(·), g2(·) and gθ(·) are user-specified link functions (e.g. the logistic or log link),
where X i1,k, X i2,k, X iθ,k are each subsets of X i,k, and where f1(·), f2(·) and fθ(·) are user-
specified functions that characterize how the respective quantities depend on the covariates.
For example, one may adopt a linear predictor specification with no interactions between the
components of X i2,k and Y1i,k−1 in the model for pi2i,k(y1) by setting f2(X i2,k, Y1i,k−1;β2) ≡
X
T
i2,kβ2,X + Y1i,k−1β2,y.
While their precise interpretations will depend on the partition of the time axis and
the chosen link functions, β = (β1,β2,βθ) characterize the impact of covariates; Section
3.4 considers the role and interpretation of components of β2 that correspond to Y1i,k−1.
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Finally, α1 = (α1,1, . . . , α1,K), α2 = (α2,1, . . . , α2,K), and αθ = (αθ,1, . . . , αθ,K) represent
baseline time trends in pi1i,k, pi2i,k(·), and θi,k, respectively, with their precise interpretation
again depending on the choice of τ , the link functions and covariates included in the models.
From a practical perspective, that α = (α1, α2, αθ) consists of 3K parameters may
result in computational and/or convergence issues unless the observed data is rich (i.e. a
large sample size or high event rates) or the initial partition is coarse. To mitigate such
issues we propose that a B-spline structure be adopted across the K components of each of
α1, α2 and αθ [7]. Towards the specification for α1, let {t˜11, . . . , t˜J11 } denote a collection of
J1 user-specified knots on the interior of the range (τ0, τK) and q1 the user-specified degree
of the local polynomial basis functions. Given these choices, we specify the kth component
of α1 as α1,k =
∑J˜1
j=1 η1,jBj,k, where Bj,k is the value of the j
th B-spline at time τk and
J˜1 = J1−1+q1 is total number of spline terms. Thus, this specification requires estimation
of J˜1 coefficient terms, specifically η1 = (η1,1, . . . , η1,J˜1). Applying the same strategy to α2
and αθ will result in J˜1 + J˜2 + J˜θ unknown coefficients, which we collectively denote as η =
(η1, η2, ηθ). Finally, to distinguish between specifications, in the remainder of this paper
we refer to the model based on α with 3K unknowns as the unstructured model while that
based on η with J˜1 + J˜2 + J˜θ unknowns as the B-spline model.
3.4 Dependence
The central innovation of the framework in expressions (5)-(7) is that dependence between
the non-terminal and terminal events is quantified in two distinct and yet complimen-
tary ways. The first is captured through θi,k which can be viewed as a measure of local
dependence in that it quantifies the risk of co-occurrence of the two events, via the odds-
ratio [30, 26, 3, 34, 23, 28], during the (τk−1, τk] interval; a large positive value of θi,k
indicates that if the non-terminal event (e.g. AD) occurs during (τk−1, τk] then the termi-
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nal event (e.g. death) is likely to subsequently occur during the same interval. Because of
the novel parameterization, we emphasize that the local dependence can vary over the time
scale or as a function of covariates. As such, one could investigate whether local dependence
between AD and death is weaker at younger ages relative to older ages. Furthermore, one
could investigate whether the probability that the two events co-occur changes in response
to key life events such as the death of a partner.
The second quantification of dependence is through the components of β2 in expression
(6) that correspond to how the status of the non-terminal event, Y1i,k−1, influences pi2i,k.
Labelling these components as β2,y, analogous to how one interprets covariates effects in
regression models, these parameters capture the extent to which whether the non-terminal
event has occurred is associated with a change in risk of the terminal event; for this reason,
we refer to β2,y as capturing global dependence. Note, global dependence is conceptually
similar to the explanatory hazard ratio (EHR) and cross-quantile residual ratio (CQRR) [40]
in that it concerns the role that the non-terminal event plays in modifying the future
occurrence of the terminal event (see Section A.1 of the Supplementary Materials).
3.5 Choice of partition
The partition, τ , plays a critical role in the proposed framework in that it provides the
foundation for being able to distinguish between local and global dependence, as we have
conceptualized them, and for being able to investigate the role that covariates play. In
Section A.4 of the Supplementary Materials we show that a distribution for (T1, T2) induces
the quantities (5)–(7) for any τ . Thus, regardless of the choice of τ , the components of
the proposed model are well-defined mathematical objects and are, therefore, valid targets
for estimation and inference. An important consequence of this is that one cannot say
that any given partition corresponds to the ‘truth’. As indicated in Section 3.2, however,
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the choice of τ dictates the numerical values and interpretation of the quantities given by
(2)-(4), and correspondingly (in part, at least) the numerical values and interpretation of
the parameters in the regression structure given by expressions (5)-(7). As such the choice
of τ is a critical challenge that requires careful consideration by the study investigators.
In principle, one could approach choosing τ through consideration of the clinical con-
dition under investigation such as the pace at which the disease progresses. In the ACT
study, for example, the choice to schedule follow-up biennially was made in part for logis-
tical considerations (it would be challenging to follow-up approximately 4,000 participants
each year) but also because AD is a slowly-developing condition. Alternatively, one may
pursue a data-driven strategy where, for example, some goodness-of-fit criterion is specified
and then optimized as a function of τ . Our perspective is that the decision should be based
primarily, if not exclusively, on clinical considerations. Central to this position is that, in
addition to their interpretation, the numerical values of (2)-(4) change with τ . To see this,
we again note that the probabilities in each of (2)-(4) speak to the cumulative incidence
of events during the interval (τk−1, τk]. If the length of the interval is decreased then the
incidence will necessarily decrease. The corresponding new interpretation and numerical
value will not be ‘wrong’, however, but just different. Put another way, the change in
the interpretation and the numerical values of the model parameters that result from, say,
adopting a finer partition of the time scale should, arguably, be viewed as a change in the
question that is being answered. Thus, in our view, purely data-driven approaches, while
they may have some initial intuitive appeal, should be avoided.
Nevertheless, we do acknowledge that it may not be easy to elicit a single partition,
from the literature or collaborators, on which to base the analyses and conclusions. If it is
the case that there is no clear choice, analysts may opt to perform a range of analyses over
different partitions, both in terms of how fine the partition is and in terms of where the
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cut-points are for a given (common) interval length. We pursue this strategy in conducting
the analyses of the data from ACT in Section 6.
4 Estimation and inference
4.1 The observed data likelihood
Building on the notation developed in Section 3, the first two columns of Table 1 provide the
six possible outcome data scenarios in the kth interval of the partition given by τ as a func-
tion of the outcome vector in the previous interval (i.e. as a function of (Y1i,k−1, Y2i,k−1)).
The third column provides the corresponding likelihood contributions, that is the interval-
specific components in the decomposition given by expression (1), with
pi12i,k = P(Y1i,k = 1, Y2i,k = 1|Y1i,k−1 = 0, Y2i,k−1 = 0,X i,k)
=
 pi1i,kpi2i,k(0) θi,k = 11
2(θi,k−1) ×
[
1 + aij −
√
(1 + ai,k)2 − 4θi,k(θi,k − 1)pi1i,kpi2i,k(0)
]
θi,k 6= 1
,
where ai,k = (pi1i,k + pi2i,k(0))(θi,k − 1) [34].
Let φ denote the collection of unknown parameters in the specification of model (5)-
(7). Note, if the unstructured form of the model is fit then φ ≡ φα = (α,β) while
φ ≡ φη = (η,β) if the B-spline model is fit. For either specification, the observed data
likelihood for a random sample of N study participants from the population of interest,
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(Y1i,k−1, Y2i,k−1) (Y1i,k, Y2i,k) Likelihood contribution
(0, 0) (0, 0) 1 − pi1i,k − pi2i,k(0) + pi12i,k
(0, 0) (1, 0) pi1i,k − pi12i,k
(0, 0) (0, 1) pi2i,k(0)− pi12i,k
(0, 0) (1, 1) pi12i,k
(1, 0) (1, 0) 1− pi2i,k(1)
(1, 0) (1, 1) pi2i,k(1)
Table 1: Six possible data scenarios for the kth interval in the partition given by τ (see Section 3)
L(φ) is the product of N terms, each of the form:
Li(φ) =
kri∏
k=kli
P(Y1i,k = y1i,k, Y2i,k = y2i,k| Y1i,k−1 = y1i,k−1, Y2i,k−1 = y2i,k−1,X i,k),
=
kri∏
k=kli
{
[pi12i,k]
y1i,ky2i,k [pi1i,k − pi12i,k]y1i,k(1−y2i,k)[pi2i,k(0)− pi12i,k](1−y1i,k)y2i,k
× [1− pi1i,k − pi2i,k(0) + pi12i,k](1−y1i,k)(1−y2i,k)
}(1−y1i,k−1)(1−y2i,k−1)
×
{
[pi2i,k(1)]
y2i,k [1− pi2i,k(1)]1−y2i,k
}y1i,k−1(1−y2i,k−1)
.
4.2 Estimation
If the unstructured form of model (5)-(7) is adopted, estimation can proceed in a straight-
forward manner by finding the maximizer of `(φα) = logL(φα), denoted by φ̂α. Under
the proposed B-spline model, however, care is needed to avoid overfitting. To resolve this,
we maximize the observed data likelihood subject to a penalty that imposes smoothness in
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resulting estimated functions. One such penalty is the integrated squared second derivative
which, following Eilers et al. [7], can be approximated by penalizing coefficient differences.
Let ∆ be the difference operator so that, for example, ∆η1,j = η1,j − η1,j−1. Then, letting
λ = (λ1, λ2, λθ), consider the penalized likelihood:
L(φη;λ) = L(φη) − λ1
J˜1∑
j=m+1
(∆mη1,j)
2 − λ2
J˜2∑
j=m+1
(∆mη2,j)
2 − λθ
J˜θ∑
j=m+1
(∆mηθ,j)
2,
where ∆m corresponds to the difference operator having been applied m times; for example,
∆2η1,j = ∆(∆η1,j) = η1,j − 2η1,j−1 + η1,j−2. Note, letting Dm denote the matrix represen-
tation of ∆m, such that, for example,
∑J˜1
j=m+1(∆
mη1,j)
2 can be written as ηT1D
T
mDmη1
(Section A.4 of the Supplementary Materials), the penalized likelihood can be written as:
L(φη;λ) = L(φη) − λ1ηT1DTmDmη1 − λ2ηT2DTmDmη2 − λθηTθDTmDmηθ. (8)
Let `(φη;λ) = logL(φη;λ) be the log-penalized likelihood. Furthermore, letU(φη;λ) =
∇
φη`(φ
η;λ) be the gradient of `(φη;λ) with respect to φη andH(φη;λ) = ∇
φφη`(φ
η;λ)
the corresponding matrix of second partial derivatives (i.e. the Hessian matrix). For a
given value of λ, the penalized maximum likelihood estimator, which we denote by φ̂
η
λ ,
is the solution to U(φη;λ) = 0. Note, since the penalty is quadratic in η1, η2, and ηθ,
gradient-based maximization is relatively straightforward to carry out.
Finally, towards choosing the value of λ on which the final results are to be based,
say λ∗, one can proceed using any standard model-selection criteria such as the Akaike
Information Criterion (AIC) or cross validation [10, 7]. In our implementation of the
methods, we follow Gray [11] by taking the trace of H(φη; 0)H−1(φη;λ) as the effective
degrees of freedom when calculating the AIC.
15
4.3 Asymptotic properties
For the unstructured model, under standard regularity conditions, the asymptotic distri-
bution for the maximum likelihood estimator φ̂
α
follows from standard likelihood theory.
That is, φ̂
α
is consistent and, letting φ˜
α
denote the value of φα induced from the partition,
N1/2(φ̂
α−φ˜α) is asymptotically normal with the variance being the usual inverse of Fisher
information matrix.
For the B-spline model, careful consideration of the asymptotic properties of φ̂
η
requires
specification of how the number of knots, J˜ = (J˜1, J˜2, J˜θ), and the penalty, λ
∗, change
with the sample size N . This has been the focus of a large body of work, much of which is
concerned with error estimation for the non-parametric function(s) [e.g., 25, 17, 4]. Here,
however, primary interest lies with statistical inference for the parameters φη. Given this,
and as recommended by number of authors for development of practical inference in a range
of setting [10, 11, 38, 41], we consider the behavior of φ̂
η
in settings where both J˜ and λ
are fixed. With this, henceforth, we denote the estimator as φ̂
η
λ .
To this end, we show in Section A.5 of the Supplementary Materials, that under stan-
dard regularity assumptions N1/2(φ̂
η
λ − φ˜
η
λ ) is asymptotically normal with variance that
can be consistently estimated by
V̂ = NH−1(φ̂η;λ)
(
1
N
N∑
i=1
U i(φ̂
η
;λ)UTi (φ̂
η
;λ)
)
NH−1(φ̂η;λ), (9)
where φ˜
η
λ is the solution of E[U(φ
η;λ)] = 0 and where U i(·;λ) is the gradient of the
log penalized likelihood of a single observation i. For individual parameters, such as the
coefficient of APOE in the model for θ, the appropriate entry in the diagonal of (9) is
used for estimating the variance. For the baseline time trends, let V̂η1 be the sub-matrix
corresponding to the estimated variance matrix of η̂1. Note that α̂1 can be written as
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α̂1 = η̂
T
1 B with B being a J˜1 ×K matrix with elements Bjk=Bj,k. Therefore, to construct
a 95% confidence interval for the AD time-varying reference probability, pi1i,k, one can use
g−11 {η̂1 ± 1.96[diag(BT V̂η1B)]1/2} where here g−1 to be understood as operating entrywise
on the vector, and diag(·) returns the diagonal of a matrix.
5 Simulation studies
We conducted a series of simulations to investigate: (i) finite sample properties of the
methods proposed in Section 4; and, (ii) the potential bias-variance trade-off that analysts
will have to contend with when choosing the degree of regularization in L(φ;λ). We note
that the simulations make no attempt to perform a comparison with existing methods (e.g.
in terms of bias or efficiency) since the proposed framework was developed to investigate
dependence in a way that is distinct, and thus complimentary, from how existing methods
approach it. We do, however, explore different approaches in the analysis of the ACT data
in Section 6. Due to space constraints, we present brief details and a summary of the main
conclusions; see Section A.6 in the Supplementary Materials for full details and results.
Building on features of the observed data from the ACT study, we generated the data
according to models (5)–(7), as a function of both time-fixed and time-dependent covariates,
under three scenarios for dependence: a null scenario, a simple dependence scenario and
a complex dependence scenario. A range of right-censoring rates (0-30%) and sizes (500-
5,000) were considered. For each scenario 1,000 datasets were generated. All simulations
were carried out using code available in the LongitSemiComp package for R. Simulation
code, seeds and results are all available online via the Github repository of the first author.
Let expit(v) = exp(v)/[1+exp(v)]. Figures A.2 and A.3 in the Supplementary Materials
summarize performance regarding estimation of time-varying functions. The time-varying
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terminal event probability function expit(α2) was well-estimated, regardless of the choice
for number of knots and the penalty level. The time-varying non-terminal probability
function expit(α1) was also well-estimated except when the number of knots was small and
a substantial amount of regularization were used (J˜ = 5 and λ ≥ 5) where the B-spline
estimator was oversmoothed, resulting in bias for later time points where less information is
available. The time-varying odds ratio function exp(αθ) was well estimated by the 10 knots
B-spline estimator, as well as by the B-spline non-smoothed 5 knots B-spline estimator.
Similar to the non-terminal probability, the 5 knots oversmoothed estimator suffered from
bias. A model with completely unrestricted α1, α2, and αθ worked well until the last
time point, where some bias was observed. Instability of the undersmoothed estimators for
time-varying odds ratio, and biased, yet stable, estimators when using excessive smoothing
were found when the sample size was small. Using AIC to choose λ, more smoothing was
desired for J˜ = 10 compared with J˜ = 5 (Table A.4).
Turning to the coefficients (Tables A.5-A.12), small finite-sample bias for β1 and β2
was mitigated under larger sample sizes. The global dependence parameter β2,y was well-
estimated, with negligible bias for all sample sizes and censoring rates. A small finite-
sample bias was observed for βθ in some of the scenarios, although it decreased as the
sample size increased. Furthermore, the bias was more substantial when the sample size
was low and the unrestricted model was used for the time-varying functions. Unpenalized
estimation under B-spline representation also resulted in bias for βθ. However, penalization
largely mitigated this bias and reduced the standard error. For larger sample sizes, this
bias disappeared. These results were consistent with the performance of the time-varying
component estimator of the odds ratio. That is, when αθ was estimated well, so was
βθ. Finally, in most cases our variance estimators performed very well, and the empirical
coverage of the confidence intervals was close to the desired nominal level.
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6 Analysis of data from the ACT study
Having ≥ 1 APOE 4 allele is well-established as a genetic risk factor for AD [2]. The
extent to which having ≥ 1 APOE 4 allele is associated with mortality, however, is un-
clear [13]; results across published studies conflict, with some indicating shorter survival
but only among men [5], some indicating no association [18] and, others indicating pro-
longed survival [36]. To the best of our knowledge, however, none of the previous studies
have examined the role of the APOE 4 allele through the lens of semi-competing risks. As
such, the opportunities that semi-competing risks analyses provide, particularly in terms
of explicit acknowledgement of death as a competing risk and in terms of being able to
learn about dependence, have not been taken advantage of.
With this backdrop, we present a detailed case study with the goal to investigate the
role of having ≥ 1 APOE 4 allele on the joint risk of AD and death, and whether this
varies by gender. Throughout, we use data from ACT with the time scale taken to be ‘time
since age 65’ or ‘time since a diagnosis of AD’, as appropriate. In reporting results we focus
on those that pertain to dependence; additional details, results and sensitivity analyses are
provided in the Supplementary Materials.
6.1 Analyses based on existing methods
Prior to presenting results based on the proposed framework, we consider a series of anal-
yses based on existing methods described in Section A.1 of the Supplementary Materials.
Results are given in Figure 2, and in Section A.6 of the Supplementary Materials.
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6.1.1 An illness-death model with a patient-specific frailty
At the outset we considered the illness-death framework, with the hazard functions for the
three transitions (i.e. Healthy ⇒ AD, Healthy ⇒ Death and AD ⇒ Death) specified via
the following Cox-type models (Section A.1):
λ1(t1;X i) = γiλ01(t1) exp{XTi ξ1}, (10)
λ2(t2;X i) = γiλ02(t2) exp{XTi ξ2}, (11)
λ3(t2|t1;X i) = γiλ03(t2 − t1) exp{XTi ξ3}, (12)
where γi ∼ Gamma(θ−1, θ−1) is a patient-specific frailty [21, 39]. Note, the model for
λ3(t2|t1; ·) is semi-Markov ; the time scale is time since diagnosis of AD. For all three
transitions, the baseline hazard is modeled as a Weibull(νg, κg), such that λ0g(t) = νgκgt
νg−1.
These choices were made because, as far as we are aware, there are no implementations of
the illness-death model, as specified by expressions (10)-(12), that permit left truncation
(a key feature of the ACT data) and anything other than Weibull baseline hazards.
Tables A.13 and A.14, and Figure A.4 in the Supplementary Materials report results for
four illness-death models, that differ in whether a patient-specific frailty was incorporated
and whether age at AD diagnosis was included in λ3(t2|t1; ·). A key observation from these
analyses is that there is little evidence that the frailties, as they are included in models
(10)-(12), serve to account for any of the dependence between the two events above and
beyond how dependence is structured through the interplay of the remaining components
of the illness-death model: the point estimates for log(θ) are −14.34 and −13.10, and the
log-likelihood at the maximum likelihood estimates are the same whether one includes the
frailties or not (Table A.14). Moreover, that the point estimates for θ are (essentially)
on the boundary of the parameter space results in the hessian evaluated at the maximum
likelihood estimates not being invertible.
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6.1.2 An illness-death model with no patient-specific frailty
Motivated by the above results, we performed additional analyses based on Cox-type spec-
ifications for the three transition-specific hazards but without the γi frailties. Note, in
removing the frailties one can estimate model components using partial likelihood methods
for Cox models where the data are subject to left truncation. We fit two semi-Markov
models, as in expressions (10)-(12), again differing in whether age at AD diagnosis was
included. We also fit a Markov model in which the AD ⇒ Death transition is modeled as:
λ3(t2|t1;X i) = λ03(t2) exp{XTi ξ3},
so that the time scale is the same as for the other two transitions (i.e. time since age 65).
Tables A.15 and A.16 in the Supplementary Materials report estimated hazard ratios
and 95% confidence intervals. Overall, the conclusions regarding the associations between
the covariates and both Alzheimer’s disease and mortality are consistent with the Weibull
illness-death model fits. Also consistent is the evidence regarding the dependence between
AD and mortality as quantified by the inclusion of age at AD diagnosis in the model for
λ3(t2|t1;X i); the estimated hazard ratio for a 5-year contrast is 1.33 (95% CI: 1.24, 1.42).
From the Markov model, since Healthy ⇒ Death and the AD ⇒ Death transitions are
modeled on the same time scale, one can report the explanatory hazard ratio for any given
patient profile. The top-left sub-figure of Figure 2 provides smoothed estimates of EHR(t2;
t1) for four profiles (Figure A.5 in the Supplementary Materials provides additional detail).
From the figure it is clear that, at any given age, the hazard for death is substantially
higher for individuals who have been diagnosed with AD relative to those who have not,
with the biggest differences among the relatively young. Intuitively, this suggests that,
among individuals at least 65 years of age, a diagnosis of AD is more devastating (from a
mortality perspective) for a young individual than for an older individual.
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Figure 2: Estimated EHRs for four patient profiles and CQRRs for the 25th quantile, the
median and 75th quantile of residual time for death, overall and stratified by whether there
was at least 1 APOE 4 allele, based on analyses of the ACT data. See Section 6.1.
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6.1.3 The cross-quantile residual ratio
Finally, we report results based on the CQRR methodology1. Specifically, we calculated
the CQRR(q; t0) at q ∈ {0.25, 0.5.0.75} (i.e. for the 25th quantile, the median and 75th
quantile of residual time for death) for ages t0 ∈ {70, . . . , 95} years, stratifying by the
number of APOE 4 alleles (0 vs ≥ 1).
Figure 2 provides estimates; see Figure A.6 in the Supplementary Materials for 95%
confidence intervals. From Figure 2, the estimated CQRR(τ ; t0) are greater than 1.0 at all
ages, indicating that residual lifetime, at any given age, for individuals without a diagnosis
of AD is estimated to be longer than that for individuals with an AD diagnosis. Compar-
ing the bottom sub-figures of Figure 2, we see that the spread in the lines is somewhat
greater for patients with no APOE 4 alleles. To interpret this, consider the population
of patients with no APOE 4 alleles and the population with at least one. In comparing
patients without an AD diagnosis to those with such a diagnosis, the distribution of resid-
ual lifetime exhibits less variation, at any given age, in the second of these populations.
Thus, a diagnosis of AD in patients with at least one APOE 4 allele results in a relatively
homogeneous decline whereas the decline associated with a diagnosis of AD in patients
with no APOE 4 alleles is more heterogeneous.
6.2 Analyses based on the proposed framework
Finally, we report results from a series of analyses using the proposed longitudinal bi-
variate modeling framework. As emphasized in Section 3.5, the choice of the partition
τ is important. Towards investigating the role of the choice, and recalling from Sec-
tion 2 that participants underwent biennial visits, we considered two partitions of the
1Using code available at http://web1.sph.emory.edu/users/lpeng/Rpackage.html
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time scale [65, 100): τ 2.5 = {65.0, 67.5, 70.0, . . . , 97.5, 100.0}, for which K=14, and τ 5.0 =
{65.0, 70.0, 75.0 . . . , 95.0, 100.0}, for which K=7. Tables A.2 and A.3 in the Supplementary
Materials provide the 2× 2 outcome tables for each interval, under the two participations.
Towards specification of the models in expressions (5)-(7), we used logit links for pi1i,k
and pi2i,k(t1), so that g
−1
1 (·) = g−12 (·) = expit(·). For the cross-sectional odds ratio, θi,k,
we used a log link, so that g−1θ (·) = exp(·). Based on these, we considered unstructured
and B-spline specifications for the three sets of baseline parameters, α1, α2 and αθ. For
the latter, we used 10 knots for τ 2.5 and 5 knots for τ 5, with a cubic spline and a second
order difference penalty (i.e. m = 2 in ∆m), and considered varying degrees of penalty,
specifically setting λ1 = λ2 = λθ = λ, with λ ∈ {0.0, 0.1, 0.5, 1.0, 2.5, 5.0}. Table A.17 in
the Supplementary Materials reports AIC from the fitted models, across the different λ.
Finally, X i1,k, X i2,k, and X iθ,k were specified with the overarching goal of assessing the
joint impact of having ≥ 1 APOE 4 allele and gender on the joint risk of AD and death. As
such, the models for pi1i,k and θi,k included main effects for having ≥ 1 APOE 4 allele and
gender, and their interaction, while the model for pi2i,k(·) included main effects, two-way
interactions and the three-way interaction between AD diagnosis, having ≥ 1 APOE 4
allele and gender. For X i1,k, X i2,k, we additionally included all other variables available
in dataset (i.e. race/ethnicity, marital status, education and depression).
6.2.1 Baseline time trends
Figure 3 reports estimated baseline time trends, that is expit(α̂1), expit(α̂2) and exp(α̂θ),
under the unstructured and B-spline specifications. Note, given the coding of the variables
included in the models, the interpretation of these quantities is specific to a population
of individuals who are cognitively intact at age 65 and have the following characteristics:
male, non-white, non-college educated, married without depression and no APOE 4 alleles.
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(b) expit(α̂1), expit(α̂2) and exp(α̂θ) under τ 5.0.
Figure 3: Estimated baseline time trends, expit(α̂1), expit(α̂2) and exp(α̂θ) from a series
of analyses to the ACT data, under the unstructured specification and the B-spline speci-
fication with λ ∈ {0.0, 2.5} and under the two partitions τ 2.5 and τ 5.0. See Section 6.2 for
details. Also shown are 95% confidence intervals. Note, the y-axis has been truncated at
0.6 for expit(α̂1) and at 10 for exp(α̂θ). For results under more λ values, see Supplementary
Figures A.7 and A.8.
Within each sub-figure, the estimates exhibit general concordance across the panels
that differ in terms of structure and smoothing. Not surprisingly, the unstructured models
exhibit greater uncertainty, especially in information-poor parts of the age scale (i.e. early
on when there are relatively few AD events). From Figure 3(a), under the B-spline analysis
with λ=2.5, the estimated baseline probability of an AD diagnosis during a given 2.5 year
age interval, conditional on being AD-free and alive at the start of the interval, increases
from 0.002 in (65.0, 67.5] to 0.10 in (97.5, 100.0]. From Figure 3(b), the same increasing
pattern emerges under partition τ 5.0 with λ=0.0, specifically from 0.004 in (65.0, 70.0]
to 0.15 in (95.0, 100.0]. Note, that this is expected since the intervals are longer and,
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correspondingly, the cumulative number of events higher. Also from Figure 3(a), we see
that the estimated baseline probability of death conditional on being event free during a
given 2.5 year age interval increases from 0.006 in (65.0, 67.5] to 0.35 in (97.5, 100.0]. Again,
the same general pattern is observed under τ 5.0, with the probability increasing from 0.01
in (65.0, 70.0] to 0.48 in (95.0, 100.0].
6.2.2 Covariate effects for AD
Based on the AIC criterion, the optimal values of λ were λ∗=2.5 and λ∗=0.0 for τ 2.5
and τ 5.0, respectively. Table 2 reports estimated covariate associations from these fits for
main effects and interactions for gender, having ≥ 1 APOE 4 allele and AD diagnosis
(as appropriate); complete results are given in Tables A.18-A.20 of the Supplementary
Materials.
From the first two columns of Table 2, the results regarding risk of AD are largely
consistent across the four sets of analyses based on the two partitions and on use of either
an unstructured or B-spline specification for the baseline time trends. Specifically, we find
that, while having ≥ 1 APOE 4 allele is a strong risk factor, there is no evidence that
gender is a risk factor nor that it is an effect modifier of the APOE effect; both point
estimates are close to the null.
6.2.3 Covariate effects for death and global dependence
The middle set of results in Table 2 speak to how gender, having ≥ 1 APOE 4 allele and
having a diagnosis of AD jointly influence risk of mortality. Note the four components
involving a diagnosis of AD correspond to β2,y in model (6) and, thus, jointly represent
global dependence between AD and mortality. As with the results regarding the risk of
AD, the results for death are largely consistent between the unstructured and baseline
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specifications. Interestingly, there are some differences between those based on the τ 2.5
partition and those based on the τ 5.0 partition although the overarching conclusion that
there is an important interplay between the three factors in determining risk of mortality is
consistent between the two. To facilitate discussion of the results, Table 3 reports odds ratio
estimates and 95% confidence intervals for mortality, based on the B-spline specification
models reported in Table 2, across combinations of whether the patient has had an AD
diagnosis, their gender, and whether they have ≥ 1 APOE 4 allele. From the first four
rows, in the absence of a diagnosis of AD, female gender is associated with approximately
40% lower odds of mortality while there is no evidence to indicate that the number of
APOE 4 alleles play a role.
AD Gender # APOE Odds ratio (95% CI)
status 4 alleles τ 2.5 τ 5.0
No AD Male 0 1.00 1.00
No AD Male ≥ 1 0.97 (0.80, 1.17) 0.98 (0.81, 1.19)
No AD Female 0 0.57 (0.51, 0.64) 0.55 (0.48, 0.62)
No AD Female ≥ 1 0.61 (0.51, 0.72) 0.61 (0.51, 0.72)
AD Male 0 2.64 (2.08, 3.34) 2.81 (2.04, 3.88)
AD Male ≥ 1 4.35 (3.09, 6.14) 6.53 (3.83, 11.1)
AD Female 0 2.35 (1.94, 2.84) 2.81 (2.17, 3.65)
AD Female ≥ 1 2.64 (2.09, 3.34) 3.54 (2.54, 4.94)
Table 3: Odds ratio estimates and 95% confidence intervals for mortality across combina-
tions of whether the patient has had an AD diagnosis, their gender, and whether they have
≥ 1 APOE 4 allele. Results are based on the B-spline models reported in Table 2.
From the lower half of Table 3, the odds of mortality among those patients with a
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diagnosis of AD diagnosis, and, thus, extent of global dependence, is substantially higher
with the magnitude depending on the interplay between gender and the number of APOE
4 alleles. Moreover, while having at least APOE 4 alleles seems to be associated with
higher odds, the increase is substantially larger for males.
6.2.4 Local dependence
Turning to the assessment of local dependence, the third row in the two sub-figures of Figure
3 suggest that there are meaningful time trends in the co-occurrence of AD and death,
specifically that the risk of co-occurrence within a given interval are highest at the early
ages. From the B-spline specification with λ=2.5 applied to partition τ 2.5, for example, the
odds ratio among males with no APOE 4 alleles decreases from 3.63 (95% CI: 1.19, 11.04)
during the (65.0, 67.5] interval to 1.37 (95% CI: 0.66, 2.86) during the (97.5, 100.0]. From
Table 2, although the confidence intervals all include 1.00, the point estimates for all three
covariates in the model applied to the τ 2.5 partition are indicative of clinically meaningful
associations. For example, the local dependence odds ratio is estimated to be 42% smaller
among males with ≥ 1 APOE 4 allele compared to those without. The corresponds odds
ratio for females is estimated to be approximately 30% smaller (0.58 × 1.20 ≈ 0.70) for
those with ≥ 1 APOE 4 allele compared to those without.
Finally, comparing the local dependence results between those based on τ 2.5 and those
based on τ 5.0 indicate that the choice of partition can have a meaningful impact on the
conclusions. This is also seen in the results regarding global dependence (see Tables 2 and
3). Moreover, under τ 5.0 the evidence regarding an interaction between gender and having
≥ 1 APOE 4 allele on local dependence is weaker when the partition intervals are 5 years
in length.
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7 Discussion
Although less familiar than competing risks, semi-competing risks arise in a wide range of
clinical settings including: Alzheimer’s disease, as illustrated in this paper; graft-versus-
host disease among patients who have undergone hematopoietic stem cell transplantation
for leukemia [8]; readmission following discharge from a hospitalization during which a pa-
tient is diagnosed of a terminal disease such as pancreatic cancer [21, 20]; shock among pa-
tients with implanted cardiac devices [32]; and, preeclampsia a severe pregnancy-associated
disease that affects between 3-10% of all pregnancies [16]. A distinguishing feature of semi-
competing risks, relative to competing risks, is that there is at least partial information
about the joint distribution between T1 and T2. In this paper, we propose a new methodol-
ogy that seeks to directly leverage this information in order to gain interpretable insight into
dependence between the two events. Because the interpretation of the model components,
including the notions of global and local dependence, are distinct from the interpretations
one obtains with existing methods, we view the proposed framework as being complimen-
tary to existing methods (as opposed to seeking to replace them). Moreover, we view
the proposed framework as being in-line with recent work that seeks to better understand
whether and how specific factors confer risk jointly on multiple outcomes, such as the dual
hazard rate proposed by Prentice and Zhao [31].
The foundation for the proposed framework is the discretization of the time scale. As
discussed in Sections 3.2 and 3.5, one cannot say that a given choice of τ is the ‘truth’
and yet the specific choice dictates the numerical values and interpretation of the results.
This results in a tension that is illustrated in Table 2: one cannot claim that either τ 2.5 or
τ 5.0 is the ‘right’ choice and yet there are instances where the numerical results differ in
meaningful ways. Our view of this dilemma is that consideration of multiple partitions can
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be viewed as an opportunity to obtain additional insight. Consider, for example, the main
effect of female gender in the model for θi,k based on the B-spline specification: under τ
2.5
the estimated impact of female gender is to reduce the local dependence odds ratio by 22%
while the reduction is only 3% under τ 5.0. Thus, ignoring the lack of statistical significance,
for the purpose of discussion, there is an indication that among individuals with no APOE
4 alleles, gender plays a role in the co-occurrence of AD and death over relatively short
time frames (i.e. 2.5 years) but not over longer time frames (i.e. 5 years). Conceptually this
is analogous to the results that one might see in a Cox model for a univariate outcome if the
effect of a covariate varies over time (i.e. non-proportional hazards) and yet proportional
hazards is adopted; in such settings, the value of the common hazard ratio that is being
estimated will depend on the interval over which data is available.
A number of extensions to the proposed framework are possible. From a theoretical
perspective, an interesting alternative to having λ fixed is to consider λ = λN = o(1); that
is the amount of regularization decreases as more data become available. This framing
of the asymptotics, however, while resulting in consistent estimation if the true functions
coincide with a B-spline, leads to a variance expression that do not involve λ and thus has
been perceived as of less useful in practice [10, 41]. Second, as mentioned in Section 2 follow-
up in ACT consists of biennial visits. As such, while the date of death can be precisely
ascertained through death records, AD is subject to interval censoring. Generalizing our
approach to interval censored data will likely be an interesting challenge, therefore, since
some event times cannot be straightforwardly assigned to a specific interval under given
a partition. Furthermore, a related problem may arise in defining covariate values when
time-dependent covariates are observed only intermittently [27].
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